Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Carlyle Group Inc (CG) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Carlyle Group IncTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Carlyle Group Inc vs Neurocrine Biosciences Inc — how do they compare? Carlyle Group Inc trades at $48.27 (market cap $17.20B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Carlyle Group Inc and Neurocrine Biosciences Inc are close in size by market cap, and Carlyle Group Inc pays a 2.93% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

CGNBIX
Market Cap
$17.20B$16.76B
Sector
FinancialsHealth
52-Week High
$69.35$185.50
52-Week Low
$40.52$123.10
Dividend Yield
2.93%
Enterprise Value
$16.78B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Carlyle Group Inc

CG trades at $47.79, down 2.23% today, with a bullish technical signal from moving averages and support at $47. Recent Q2 2026 earnings beat expectations (EPS $1.07 vs. $0.911), though revenue declined to $2.9B in 2026. The company maintains a strong net income margin of 18.85% and announced strategic partnerships, including a $600M deal with Prime Capital Financial (Business Wire, 2026-08-06).

Outlook is mixed: analyst consensus is bullish with a $59.14 price target (53.84% buy ratings), but risks include volatile cash flow from operations (-$4.2B in 2026) and high P/E of 49.78. Investors may see upside from fundraising strength, though margin compression and macroeconomic headwinds warrant caution.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.

The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Carlyle Group Inc

The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.

Read more on CG

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX